{"meta":{"totalResults":3,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Velcade"},{"type":"CodeName","name":"MLN341"},{"type":"CodeName","name":"LDP 341"},{"type":"LexicalVariant","name":"LDP-341"},{"type":"LexicalVariant","name":"LDP341"},{"type":"CodeName","name":"PS-341"},{"type":"Synonym","name":"PS-341"},{"type":"LexicalVariant","name":"PS341"},{"type":"ChemicalStructureName","name":"[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid"},{"type":"INDCode","name":"58443"},{"type":"NSCNumber","name":"681239"},{"type":"CASRegistryName","name":"179324-69-7"}],"definition":{"html":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","text":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/bortezomib","text":"Bortezomib"},"nciConceptId":"C1851","nciConceptName":"Bortezomib","termId":43560,"name":"bortezomib","firstLetter":"b","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"bortezomib"},{"aliases":[{"type":"Synonym","name":"bortezomib-doxorubicin-dexamethasone regimen"},{"type":"Synonym","name":"bortezomib/doxorubicin/dexamethasone regimen"},{"type":"Synonym","name":"Velcade/adriamycin/dexamethasone regimen"},{"type":"Abbreviation","name":"PAD"},{"type":"Synonym","name":"bortezomib/ dexamethasone/doxorubicin"},{"type":"Synonym","name":"PS-341/Adriamycin/dexamethasone regimen"}],"definition":{"html":"A chemotherapy regimen containing bortezomib, doxorubicin and dexamethasone regimen used in the treatment of plasma cell myeloma.","text":"A chemotherapy regimen containing bortezomib, doxorubicin and dexamethasone regimen used in the treatment of plasma cell myeloma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/PAD","text":"PAD"},"nciConceptId":"C114387","nciConceptName":"PAD Regimen","termId":759138,"name":"PAD regimen","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pad-regimen"},{"aliases":[{"type":"Synonym","name":"bortezomib/melphalan/prednisone"},{"type":"Synonym","name":"melphalan/prednisone/bortezomib"},{"type":"Synonym","name":"melphalan-prednisone-bortezomib regimen"},{"type":"Synonym","name":"melphalan/prednisone/Velcade"},{"type":"Abbreviation","name":"MPB"},{"type":"Synonym","name":"MPB regimen"},{"type":"Abbreviation","name":"MPV"},{"type":"Synonym","name":"Velcade/melphalan/prednisone"},{"type":"Abbreviation","name":"VMP"}],"definition":{"html":"A regimen consisting of melphalan, prednisone and bortezomib used for the treatment of plasma cell myeloma.","text":"A regimen consisting of melphalan, prednisone and bortezomib used for the treatment of plasma cell myeloma."},"drugInfoSummaryLink":null,"nciConceptId":"C64836","nciConceptName":"VMP Regimen","termId":802163,"name":"VMP regimen","firstLetter":"v","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"vmp-regimen"}],"links":null}